Amyloid β concentrations in older people with Down syndrome and dementia

Neuroscience Letters

Volumn 451, Issue 2, 2009, Pages 162-164

  Jones, Emma L ^a   Hanney, Marisa ^b   Francis, Paul T ^a   Ballard, Clive G ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Northgate Hospital   (United Kingdom)

Author keywords

Alzheimer's disease; Amyloid beta; Down syndrome; Plasma

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42];

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DEMENTIA; DISEASE COURSE; DOWN SYNDROME; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; AGE FACTORS; AGED; AGING; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; APOLIPOPROTEINS E; BIOLOGICAL MARKERS; COMORBIDITY; DOWN SYNDROME; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; SEX FACTORS;

EID: 58849163660     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2008.12.030     Document Type: Article

References (21)

1. Beyreuther K., Pollwein P., Multhaup G., Monning U., Konig G., Dyrks T., Schubert W., and Masters C.L. Regulation and expression of the Alzheimer's beta/A4 amyloid protein precursor in health, disease, and Down's syndrome. Ann. N.Y. Acad. Sci. 695 (1993) 91-102
2. Cook C.N., Hejna M.J., Magnuson D.J., and Lee J.M. Expression of calcipressin 1, an inhibitor of the phosphatase calcineurin, is altered with aging and Alzheimer's disease. J. Alzheimers Dis. 8 (2005) 63-73
3. Iwatsubo T., Mann D.M., Odaka A., Suzuki N., and Ihara Y. Amyloid beta protein (A beta) deposition: A beta 42(43) precedes A beta 40 in Down syndrome. Ann. Neurol. 37 (1995) 294-299
4. Jones E.L., Margallo-Lana M., Prasher V.P., and Ballard C.G. The extended tau haplotype and the age of onset of dementia in Down syndrome 26 (2008) 199-202
5. Kimura R., Kamino K., Yamamoto M., Nirupa A., Kida T., Kazui H., Hashimoto R., Tanaka T., Kudo T., Yamagata H., Tabara Y., Miki T., Akatsu H., Kosaka K., Funakoshi E., Nishitomi K., Sakaguchi G., Kato A., Hattori H., Uema T., and Takeda M. The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between β-amyloid production and tau phopshorylation in Alzheimer disease. Hum. Mol. Genet. 16 (2007) 15-23
6. Margallo-Lana M., Morris C.M., Gibson A.M., Tan A.L., Kay D.W., Tyrer S.P., Moore B.P., and Ballard C.G. Influence of the amyloid precursor protein locus on dementia in Down syndrome. Neurology 62 (2004) 1996-1998
7. Margallo-Lana M.L., Moore P.B., Kay D.W., Perry R.H., Reid B.E., Berney T.P., and Tyrer S.P. Fifteen-year follow-up of 92 hospitalized adults with Down's syndrome: incidence of cognitive decline, its relationship to age and neuropathology. J. Intellect. Dis. Res. 51 (2007) 463-477
8. M.L. Margallo-Lana, Age related neurocognitive changes in adults with Down's syndrome, Doctoral Thesis, Newcastle University, 2004.
9. Mehta P.D., Capone G., Jewell A., and Freedland R.L. Increased amyloid β protein levels in children and adolescents with Down syndrome. J. Neurol. Sci. 254 (2007) 22-27
10. Mehta P.D., Dalton A.J., Mehta S.P., Kim K.S., Sersen E.A., and Wisniewski H.M. Increased plasma amyloid β protein 1-42 levels in Down syndrome. Neurosci. Lett. 241 (1998) 13-16
11. Mehta P.D., Mehta S.P., Fedor B., Patrick B.A., Emmerling M., and Dalton A.J. Plasma amyloid β protein 1-42 levels are increased in old Down syndrome but not in young Down syndrome. Neurosci. Lett. 342 (2003) 155-158
12. Murphy Jr. G.M., Eng L.F., Ellis W.G., Perry G., Meissner L.C., and Tinklenberg J.R. Antigenic profile of plaques and neurofibrillary tangles in the amygdala in Down's syndrome: a comparison with Alzheimer's disease. Brain Res. 537 (1990) 102-108
13. Prasher V.P., and Krishnan V.H. Mental disorders and adaptive behaviour in people with Down's syndrome. Br. J. Psychiatry 162 (1993) 848-850
14. Schupf N., Kapell D., Lee J.H., Zigman W., Canto B., Tycko B., and Mayeux R. Onset of dementia is associated with apolipoprotein E ε4 in Down syndrome. Ann. Neurol. 40 (1996) 799-801
15. Schupf N., Patel B., Silverman W., Zigman W.B., Zhong N., Tycko B., Mehta P.D., and Mayeux R. Elevated plasma amyloid β-peptide 1-42 and onset of dementia in adults with Down syndrome. Neurosci. Lett. 301 (2001) 199-203
16. Sobow T., and Kloszewska I. Short-tern treatment with rivastigmine and plasma Ab peptides in Alzheimer's disease. Folia Neuropathol. 43 (2005) 340-344
17. Teller J.K., Russo C., DeBusk L.M., Angelini G., Zaccheo D., Dagna-Bricarelli F., Scartezzini P., Bertolini S., Mann D.M., Tabaton M., and Gambetti P. Presence of soluble amyloid β-peptide precedes amyloid plaque formation in Down syndrome. Nat. Med. 2 (1996) 93-95
18. Tokuda T., Fukushima T., Ikeda S., Sekijima Y., Shoji S., Yanagisawa N., and Tamaoka A. Plasma levels of amyloid β proteins Aβ1-40 and Aβ1-42(43) are elevated in Down's syndrome. Ann. Neurol. 41 (1997) 271-273
19. W.A. van Gool, H.M. Evenhuis, C.M. van Duijn on behalf of the Dutch study group on Down's syndrome and ageing, A case-control study of apolipoprotein E genotypes in Alzheimer's disease associated with Down's syndrome, Ann. Neurol. 38 (1995) 225-230.
20. Wisniewski K.E., Dalton A.J., McLachan C., Wen G.Y., and Wisniewski H.M. Alzheimer's disease in Down's syndrome: clinicopathological studies. Neurology 35 (1985) 957-961
21. World Health Organisation. International Classification of Diseases. 10th ed. (1992), WHO, Geneva